SCHEMBL11807

SCHEMBL11807

Cn1nc(-c2cc(O)cc(Cl)c2)c2c(N)ncnc21

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 18/20 0.60
BTK Q06187 1/20 0.60
PIK3CA P42336 16/20 0.59
PIK3CB P42338 16/20 0.59
PIK3CG P48736 16/20 0.59
PRKDC P78527 16/20 0.59
ABL1 P00519 14/20 0.59
EGFR P00533 14/20 0.59
HCK P08631 14/20 0.59
SRC P12931 14/20 0.59
MTOR P42345 14/20 0.59
EPHB4 P54760 14/20 0.59
KDR P35968 13/20 0.59
PI4KB Q9UBF8 7/20 0.59
NUDT14 O95848 1/20 0.50
NUDT5 Q9UKK9 1/20 0.50
RIPK1 Q13546 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23917265 0.87 PIK3CD (0.62) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL129487 0.85 PIK3CD (0.72) PIK3CDBTKPIK3CAPIK3CBPIK3CG
SCHEMBL129879 0.82 PIK3CD (0.57) PIK3CDBTKPIK3CAPIK3CBPIK3CG
SCHEMBL12192 0.82 PIK3CD (0.53) PIK3CDBTKPIK3CAPIK3CBPIK3CG
SCHEMBL130589 0.81 PIK3CG (0.74) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL130419 0.80 PIK3CD (0.70) PIK3CDBTKPIK3CAPIK3CBPIK3CG
SCHEMBL13019672 0.80 SRC (0.69) PIK3CDBTKPIK3CAPIK3CBPIK3CG
SCHEMBL23917522 0.79 PIK3CD (0.62) PIK3CDBTKPIK3CAPIK3CBPIK3CG
SCHEMBL23917458 0.79 PIK3CD (0.62) PIK3CDBTKPIK3CAPIK3CBPIK3CG
SCHEMBL4275166 0.79 PIK3CD (0.71) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2021-06-01 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-09-19 US disclosed
US-10322130-B2 Substituted chromenones as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-06-18 US disclosed
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-04-11 US disclosed
US-10220035-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-03-05 US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
WO-2012151525-A9 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-12-13 WO disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed
WO-2012151525-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-08 WO disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 PIK3CD 2/4885BTK 345/4885PIK3CA 4/4885
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases MAP4K2, MAP3K20, MAP3K1 PIK3CD 288/4885BTK 203/4885PIK3CA 221/4885
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB PIK3CD 47/4885BTK 346/4885PIK3CA 88/4885
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKAR2B PIK3CD 89/4885BTK 369/4885PIK3CA 106/4885
US-10220035-B2 Compounds as modulators of protein kinases PRKCA, PRKCH, PRKCE PIK3CD 30/4885BTK 311/4885PIK3CA 64/4885
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB PIK3CD 47/4885BTK 346/4885PIK3CA 88/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885BTK 458/4885PIK3CA 143/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885BTK 458/4885PIK3CA 143/4885
US-10322130-B2 Substituted chromenones as modulators of protein kinases MAP3K1, CSNK1A1, MAP3K2 PIK3CD 148/4885BTK 204/4885PIK3CA 153/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A PIK3CD 103/4885BTK 277/4885PIK3CA 144/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885BTK 458/4885PIK3CA 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.